Persistent Tardive Dyskinesia After Antipsychotic Dose Reduction
Tardive dyskinesia that persists despite reduction of an offending antipsychotic should be treated as persistent TD rather than as an unresolved dose-related adverse effect. Reassessment for contributing factors is recommended, followed by pharmacologic treatment for moderate to severe or disabling TD with a reversible VMAT2 inhibitor. [1]
Medication Selection Algorithm
A reversible VMAT2 inhibitor is recommended for moderate to severe or disabling tardive dyskinesia associated with antipsychotic therapy. [1]
- VMAT2 inhibitors (including valbenazine and deutetrabenazine) [1]
- Valbenazine is generally preferred over tetrabenazine for tolerability in many patients due to a lower evidence base for tetrabenazine and differences in hepatic and renal restrictions. [1]
Key Evidence Supporting This Recommendation
In the APA evidence synthesis for VMAT2 inhibitors, deutetrabenazine was associated with a significant decrease in total AIMS scores in 2 double-blind, placebo-controlled RCTs (SMD −0.40, 95% CI −0.19 to −0.62, P<0.001; N=413), and with a significantly greater rate of response. [1]
In the same APA evidence synthesis, valbenazine trials (4 double-blind, placebo-controlled trials; total N=488) demonstrated statistically significant improvement on AIMS versus placebo. [1]
Monotherapy Versus Combination Therapy
VMAT2 inhibitor treatment is recommended as monotherapy for moderate to severe or disabling TD when the condition persists after dose reduction of the offending antipsychotic. [1]
Avoidance of escalation strategies that increase anticholinergic burden for TD is recommended due to lack of usefulness for tardive dyskinesia. [1]
Important Clarifications and Nuances
Lowering antipsychotic dose or changing antipsychotic therapy can be associated with increased psychotic symptoms. [1]
Anticholinergic medications are not useful for treating tardive dyskinesia. [1]
Initiation Thresholds and Indications
A reversible VMAT2 inhibitor is recommended when tardive dyskinesia is moderate to severe or disabling and is associated with antipsychotic therapy. [1]
A VMAT2 inhibitor may be considered for mild tardive dyskinesia based on patient preference, associated impairment, or effect on psychosocial functioning. [1]
Common Pitfalls to Avoid
Anticholinergic agents should not be used as a primary treatment for tardive dyskinesia because they are not useful for TD. [1]
Management should avoid strategies that increase risk of harms from other antipsychotic adverse effects, including through reflexive dose increases, since dose reduction can increase psychotic symptoms and may necessitate careful balancing of movement symptoms against psychiatric stability. [1]
Targets and Ongoing Monitoring
Improvement should be monitored using a standardized movement scale such as the AIMS to track motor sign and symptom reduction with VMAT2 inhibitor therapy. [1]
Ongoing monitoring should include evaluation for VMAT2 inhibitor tolerability, including sedation, and attention to potential adverse effects described in the APA guideline summary. [1]
AAN guideline-supported adjunctive options for tardive syndromes (not VMAT2 inhibitors) are limited to agents with evidence grades such as clonazepam (Level B) and ginkgo biloba (Level B) for TD, based on the AAN 2013 guideline. [2]